A New Edition of Cambridge Quarterly of Healthcare Ethics Is Now Available
September 17, 2019
Cambridge Quarterly of Healthcare Ethics (vol. 28, no. 1, 2019) is available online by subscription only.
Articles include:
- “Introduction: The Ethical Frontiers of Gene Editing” by Arthur Caplan and Vojin Raki?
- “Why We Should Defend Gene Editing as Eugenics” by Nicholas Agar
- “Gene Doping—in Animals? Ethical Issues at the Intersection of Animal Use, Gene Editing, and Sports Ethics” by Carolyn P. Neuhaus and Brendan Parent
- “Genome Editing for Involuntary Moral Enhancement” by Vojin Raki?
- “Can the Thought of Teilhard de Chardin Carry Us Past Current Contentious Discussions of Gene Editing Technologies?” by Mária Šuleková and Kevin T. Fitzgerald
- “Regulating Genome Editing: For an Enlightened Democratic Governance” by Giulia Cavaliere, Katrien Devolder, and Alberto Giubilini
- “Gene Drives and Genome Modification in Nonhuman Animals: A Concern for Informed Consent?” by Joanna Smolenski
- “Let Us Assume That Gene Editing is Safe—The Role of Safety Arguments in the Gene Editing Debate” by Søren Holm
- “A Defense of Limited Regulation of Human Genetic Therapies” by James J. Hughes
- “Editorial: Looking for Justice from the Health Industry” by Doris Schroeder and Julie Cook
- “Continued Access to Investigational Medicinal Products for Clinical Trial Participants—An Industry Approach” by Ariella Kelman, Anna Kang, and Brian Crawford
- “Healthy Volunteers for Clinical Trials in Resource-Poor Settings: National Registries Can Address Ethical and Safety Concerns” by Francois Bompart
- “Involving Patients in Research? Responsible Research and Innovation in Small- and Medium-Sized European Health Care Enterprises” by Kalypso Iordanou
- “Working Together to Make the World a Healthier Place: Desiderata for the Pharmaceutical Industry” by Klaus M. Leisinger and Kate Chatfield
